Anticoagulation in Patients With Venous Thromboembolism and Cancer

Back to Search
Print
Bookmark Trial

NCT04618913

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
London, , , United Kingdom
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms, Embolism
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-99 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- A VTE diagnosis

- Active cancer or history of cancer

- Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH

- Age ≥ 18 years at the date of index VTE (Venous thromboembolic)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior VTE diagnosis


- Diagnosis of prior atrial fibrillation


- Inferior Vena Cava (IVC) filter


- Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation -
note: Prophylactic use of (OAC)/(PAC) allowed.


- Pregnancy


- More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed
on the index date.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Neoplasms, EmbolismAnticoagulation in Patients With Venous Thromboembolism and Cancer
NCT04618913
  1. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Anticoagulation in Patients With Venous Thromboembolism and Cancer
Official Title VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe)
Brief Summary This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Adult patients with a diagnosis of (VTE) venous thromboembolism and active cancer, or a history of cancer, being treated with anticoagulation.
Condition
  • Neoplasms
  • Embolism
Intervention
  • Drug: Apixaban
    Anticoagulant
  • Drug: Rivaroxaban
    Anticoagulant
  • Drug: Edoxaban
    Edoxaban
  • Drug: Dabigatran
    Dabigatran
  • Drug: VKA
    Vitamin K antagonist
  • Drug: LMWH
    Low Molecular Weight Heparin
Study Groups/Cohorts
  • VTE and history of cancer
    VTE and history of cancer
    Interventions:
    • Drug: Apixaban
    • Drug: Rivaroxaban
    • Drug: Edoxaban
    • Drug: Dabigatran
    • Drug: VKA
    • Drug: LMWH
  • VTE and active cancer
    VTE and active cancer
    Interventions:
    • Drug: Apixaban
    • Drug: Rivaroxaban
    • Drug: Edoxaban
    • Drug: Dabigatran
    • Drug: VKA
    • Drug: LMWH
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: November 1, 2020)		1
Original Estimated Enrollment Same as current
Estimated Study Completion Date September 30, 2021
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • A VTE diagnosis
  • Active cancer or history of cancer
  • Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
  • Age ? 18 years at the date of index VTE (Venous thromboembolic)

Exclusion Criteria:

  • Prior VTE diagnosis
  • Diagnosis of prior atrial fibrillation
  • Inferior Vena Cava (IVC) filter
  • Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed.
  • Pregnancy
  • More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date.
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number NCT04618913
Other Study ID Numbers B0661150
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2020